Stimulation of the STING pathway leads to inhibition of HBV replication: insights into the role of hepatic macrophages.

Ming-Yuan Zhang Xiao-Mei Wang Hong-Qin Xu Hao Meng Jie Zhou Xiao-Yu Wen Ying-Yu Zhang Jinglan Jin Q. Jin G. Lee Yan-Hang Gao Jun-Qi Niu

Aug 2026 · Journal of Infectious Diseases · 0 citations

Medicine

TL;DR

STING pathway activation enhances the immune response against HBV by upregulating the expression of immune-related genes and boosting the immune response against HBV.

DOI PubMed Semantic Scholar

View source

Similar papers

Oct 2026

Toll-like Receptor 7 and Interferon-α Synergy Establishes a Positive Feedback Loop to Potentiate Antiviral Immunity in Chronic Hepatitis B.

BACKGROUND AND OBJECTIVES Current therapies for chronic hepatitis B (CHB) rarely achieve functional cure, underscoring the need for novel immunotherapies. Toll-like receptor 7 (TLR7), a key innate immune sensor, has emerged as a major drug development focus. This study aims to characterize stage-specific TLR7 expressio...

J. Ge, Zi-Mo Chen, Xuan Huang et al. · Antiviral Research · 0 citations

Open access Oct 2026

SARS-CoV-2 spike protein enhances HBV replication via autophagy and aggravates inflammation in CHB patients with liver dysfunction

ABSTRACT This study investigated the effects of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein) on hepatitis B virus (HBV) replication and immune function in patients with chronic hepatitis B (CHB), aiming to elucidate the underlying mechanisms of S protein–HBV interaction. Th...

Liang-Juan Chen, Yu-Fen Jiang, Xing-Zhong Miao et al. · Microbiology spectrum · 0 citations

Open access Sep 2026

Intracellular Zn2+ levels regulate susceptibility to hepatitis B virus infection by modulating NTCP-mediated viral entry.

Hepatitis B virus (HBV) infection remains a significant global health challenge and is a leading cause of chronic liver diseases, including cirrhosis and hepatocellular carcinoma. Although nucleos(t)ide analogs and interferon-based therapies suppress viral replication, they do not eliminate the viral reservoir, highlig...

Yumi Itoh, Chiharu Morita, Jin-Zi Cui et al. · Antiviral Research · 0 citations

Review Open access Jan 2026

Research Progress on Mechanisms of Immune Tolerance Induced by Hepatitis B Surface Antigen in Chronic HBV Infection

The sustained elevation of hepatitis B surface antigen (HBsAg) facilitates the progression of chronic hepatitis B virus (HBV) pathogenesis, and initiates and sustains host immune tolerance. Immune tolerance is a major factor contributing to viral persistence and viral clearance failure. HBsAg exerts regulatory effects...

Li Wang · Journal of Immunological Res... · 0 citations

Review Open access Oct 2026

Host restriction factors in HBV-related liver disease and hepatocellular carcinoma: mechanisms of viral-host interplay and implications for therapy.

Chronic hepatitis B virus (HBV) infection is a leading cause of liver cirrhosis and hepatocellular carcinoma (HCC), imposing a substantial global health burden. The natural history of persistent HBV infection progresses from chronic inflammation to fibrosis, cirrhosis, and malignant transformation, driven in part by th...

Ze-Pei Li, Ye Qiu, Tom Luedde et al. · Cellular and Molecular Gastr... · 0 citations

Open access Sep 2026

RNAi-mediated HBV antigen shutdown enhances the antiviral immune effects of PEGIFNα via T and B cell crosstalk remodeling.

Backgrounds/Aims PEGylated interferon-α (PEGIFNα) shows promise in treating chronic hepatitis B (CHB), yet patient response remains suboptimal. While suppressing hepatitis B virus (HBV) antigens by RNA interference (RNAi) could enhance PEGIFNα efficacy in CHB patients, the underlying immunological mechanisms remain obs...

Wenjing Zai, Kong-Ying Hu, Meng-Ying He et al. · Clinical and Molecular Hepat... · 0 citations